Table 1 |
|||||
|
Literature review of ring 18 cases in acute myelogenous leukemia |
|||||
|
Karyotype [Number of cells] |
Antecedent disease |
Disease |
Treatment |
Followup |
Reference |
|
|
|||||
|
45, XY, der(1)t(1;11)(p36;q23), -11, dmin(18)46, XY, r(18), dmin(1) [NA]/46, WY, dmin(1) |
MDS |
AML-M4 |
ARA-C |
Died |
Michalova et al[10] |
|
46, XX, r18(p11q21) [NA]/46, XX |
Hodgkin's disease |
NA |
NA |
NA |
Lee et al[4] |
|
46, XY, r(18)(p11q23)[9%] |
NA |
AML-M4 |
NA |
18+months |
Testa et al[5] |
|
43-46, XX, -3, -5, -7, +8, r(18), +20, dmin[cp19]/46, XX[1] |
Multiple myeloma |
AML |
VAD MP VMCP VBAP |
NA |
Sawyer et al[11] |
|
r(18) and r(20) present. Full karyotype not available |
NA |
AML |
NA |
NA |
Gisselsson et al[12] |
|
47, +21, r(?18)[31] |
NA |
AML-either M1 or M2 |
NA |
NA |
Fitzgerald et al[13] |
|
39-44, Y, der(X)t(X;9) (p11.2;?q32), del(1)(p13p32), t(1;10)(p21;q26), der(5)t(X;5)(p11.2;q11), -9, der(?16)r(16; 18)(?;?q11?q12), der(17)t(9;17)(?;p11), -18[cp3] |
NA |
tAML |
NA |
NA |
Mrozek et al[14] |
|
44, XX, del(2p), del(5q), - 7, - 9, - 14, der(l7]<i(l7p)?>, -18, r(18), - 21, + 22, + mar.variations [21] |
NA |
AML-M4 |
NA |
NA |
GFCH[15] |
|
Ring 18 present but karyotype not available so unclear if this is a sole abnormality |
NA |
NA |
NA |
NA |
Schoch et al[16] |
|
45, XX, -7. r(18)[15] |
NA |
AML-M6 |
NA |
Lost to followup |
Gibbons et al[17] |
|
|
|||||
|
NA: not available; VAD: vincristine, adriamycin, dexamethasone; MP: melphalan, prednisone; VMCP: vincristine, melphalan, cyclophosphamide, prednisone; VBAP: vincrisitne, carmustine, doxorubicine, prednisone; CY: cyclophosphamide; TBI-F10: total body irradiation in fractionated doses of 10 Gy |
|||||
|
Sivendran et al. Journal of Hematology & Oncology 2010 3:25 doi:10.1186/1756-8722-3-25 |
|||||
